Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Leases (2019 - 2025)

Iovance Biotherapeutics has reported Leases over the past 4 years, most recently at $45.9 million for Q4 2025.

  • Quarterly results put Leases at $45.9 million for Q4 2025, down 16.85% from a year ago — trailing twelve months through Dec 2025 was $45.9 million (down 16.85% YoY), and the annual figure for FY2025 was $45.9 million, down 16.85%.
  • Leases for Q4 2025 was $45.9 million at Iovance Biotherapeutics, down from $48.8 million in the prior quarter.
  • Over the last five years, Leases for IOVA hit a ceiling of $71.5 million in Q1 2024 and a floor of $45.9 million in Q4 2025.
  • Median Leases over the past 3 years was $58.9 million (2023), compared with a mean of $58.9 million.
  • Biggest five-year swings in Leases: increased 1.54% in 2024 and later fell 28.82% in 2025.
  • Iovance Biotherapeutics' Leases stood at $62.5 million in 2023, then dropped by 11.7% to $55.2 million in 2024, then fell by 16.85% to $45.9 million in 2025.
  • The last three reported values for Leases were $45.9 million (Q4 2025), $48.8 million (Q3 2025), and $49.9 million (Q2 2025) per Business Quant data.